Clinical Trial Update: Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors [Phase 1]

View source ↗

Summary

Completion of a Phase 1 dose-confirmation and dose-expansion study evaluating IO-108 alone and in combination with an Anti-PD-1 therapy in patients with advance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Anti-PD-1 therapy
• IO-108 (IO-108)

Snippet

Sponsor: Immune-Onc Therapeutics | Conditions: Advanced Solid Tumor | Phase 1 | Status: COMPLETED